ACET
Adicet Bio Inc

3,762
Mkt Cap
$136.4M
Volume
0.00
52W High
$1.48
52W Low
$0.4471
PE Ratio
-0.68
ACET Fundamentals
50D MA
$0.8243
Beta
0.89
Avg. Volume
403,297.38
EPS (Annual)
-$1.33
P/B
0.56
Rev/Employee
$0.00
Loading...
Loading...
News
all
press releases
Adicet Bio Announces First Patient Dosed in Phase 1 Clinical Trial of ADI-001 in Treatment-Refractory Rheumatoid Arthritis (RA)
Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced that the...
Business Wire·9d ago
News Placeholder
More News
News Placeholder
Are Medical Stocks Lagging Exact Sciences (EXAS) This Year?
Here is how Exact Sciences (EXAS) and Adicet Bio, Inc. (ACET) have performed compared to their sector so far this year.
Zacks·18d ago
News Placeholder
Adicet Bio (ACET) Upgraded to Buy: Here's What You Should Know
Adicet Bio (ACET) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Zacks·25d ago
News Placeholder
Adicet Bio (ACET) Upgraded to Buy: Here's Why
Adicet Bio (ACET) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Zacks·2mo ago
News Placeholder
Adicet Bio shares rise on FDA Fast Track Designation for ADI-001
Investing.com -- Adicet Bio shares jumped 6.4% premarket after the company announced that the U.S. Food and Drug Administration (FDA) granted Fast Track Designation to its investigational therapy ADI-001 for the treatment of systemic sclerosis (SSc).
investing.com·8mo ago
News Placeholder
Here’s Why Shuttle Pharma is the Most Undervalued Biotech Stock in Our Coverage Universe
Stocktwits Contributor·8mo ago
News Placeholder
Adicet Bio Receives FDA Fast Track Designation for ADI-001 for the Treatment of Refractory Systemic Lupus Erythematosus (SLE) with Extrarenal Involvement
Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced the U.S...
Business Wire·9mo ago
News Placeholder
Adicet Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced it...
Business Wire·9mo ago
News Placeholder
Adicet Bio to Participate in a Fireside Chat at the Guggenheim Securities SMID Cap Biotech Conference
Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced that...
Business Wire·9mo ago
News Placeholder
Adicet Bio Provides Corporate Update and Highlights Expected 2025 Milestones
Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today provided corporate...
Business Wire·10mo ago

Latest ACET News

View

Advertisement|Remove ads.

Advertisement|Remove ads.